Management of asthma in the elderly patient

Andrea S Melani
Fisiopatologia e Riabilitazione Respiratoria, Dipartimento Vasi, Cuore e Torace, Policlinico Le Scotte, Azienda Ospedaliera Universitaria Senese, Siena, Italy

Abstract: A significant number of older asthmatics, more often than in previous ages, have poorly controlled asthma, leading to increased morbidity and mortality. On the other hand, current guidelines suggest that most asthmatics can obtain achievement and maintenance of disease control and do not include sections specific to the management of asthma in the elderly so that it is more evident the contrast between poor control of asthma in the elderly and the lack of specific guidance from guidelines on asthma management in older asthmatics. Inhaled corticosteroids are the cornerstone for older asthmatics, eventually with add-on inhaled long-acting beta-agonists; inhaled short acting beta-agonists can be used as rescue medications. Triggers exacerbating asthma are similar for all ages, but inhaled viruses and drug interactions have greater clinical significance in the elderly. Older asthmatics have an increased likelihood of comorbidities and polypharmacy, with possible worsening of asthma control and reduced treatment adherence. Physicians and older asthmatics probably either do not perceive or accept a poor asthma control. We conclude that specific instruments addressed to evaluate asthma control in the elderly with concomitant comorbidities and measurements for improving self-management and adherence could assure better disease control in older asthmatics.

Keywords: asthma, beta2-agonists, inhaled corticosteroids, asthma control, elderly

Introduction

Asthma is a chronic inflammatory bronchial disease associated with airway hyperresponsiveness, variable airflow obstruction, and episodes of wheezing, breathlessness, and cough; although these symptoms are common to many other diseases, in asthma they have a marked variability in response to a range of environmental stimuli, such as inhaled viruses, allergens, and drugs, often permitting the suspicion of diagnosis on a clinical basis (see Table 1).1-5

Asthma is widespread for all classes of age, including the elderly. The term elderly usually refers to persons aged 65 years or older, a largely increasing population worldwide. The physician-diagnosed prevalence of asthma in older adults is between 6% and 10%, just as in any other age group.6 Asthma in older adults is either diagnosed after the age of 65 years or with a history of long-standing disease. In a cohort study of 1485 older asthmatics recruited by chest physicians, almost a quarter were diagnosed after 65 years.7

The goal of asthma treatment is achievement and maintenance of disease control.1-5 Uncontrolled asthma is more common in older adults than in previous ages with a substantial clinical burden, a greater proportion of asthma medications prescriptions, hospitalizations, and death.8-13
The aim of this study is to assess the current modalities of asthma management in the elderly with reference to causes of uncontrolled disease and possible adjustments. Management of acute asthma is beyond the scope of the present work and will not be relevant on the topic. The PubMed database was searched using the keywords “asthma” in combination with “elderly” or “aging” or “older” up to March 2013. The selection of articles was not systematic. Studies were not graded by criteria defined a priori.

### Table 1 Diagnosis of asthma based on medical history, physical examination, and objective measurements

<table>
<thead>
<tr>
<th>Key elements of medical history</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Cough</td>
</tr>
<tr>
<td>- Wheezing</td>
</tr>
<tr>
<td>- Breathlessness</td>
</tr>
<tr>
<td>- Chest tightness</td>
</tr>
<tr>
<td>- Family or personal history of allergic or atopic disease</td>
</tr>
</tbody>
</table>

Assess for symptom patterns typical of asthma
- Episodic or recurrent
- Occur or worsen upon exposure to allergens, respiratory infections, irritants such as pollutants, exercise, tobacco smoke, or drugs
- Good response to a bronchodilator

**Physical examination**
- Wheezing on lung auscultation
- Concomitant rhinitis

**Objective measurements**
- Spirometry showing reversible airway obstruction: reduced FEV₁/FVC and increase in FEV₁ after a bronchodilator ≥12% and ≥200 mL or after a course of controller therapy
- Alternative: peak expiratory flow variability: ≥60 lpm or ≥20% based on multiple daily readings

If spirometry (or PEF) is normal, but symptoms are present consider
- Challenge testing
- Allergy testing
- Skin testing
- Specific serum IgE testing

**Abbreviations:** FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; IgE, serum immunoglobulin E; PEF, peak expiratory flow.

The aim of this study is to assess the current modalities of asthma management in the elderly with reference to causes of uncontrolled disease and possible adjustments. Management of acute asthma is beyond the scope of the present work and interested readers are referred to other reviews.

This review includes results from the literature judged to be relevant on the topic. The PubMed database was searched using the keywords “asthma” in combination with “elderly” or “aging” or “older” up to March 2013. The selection of articles was not systematic. Studies were not graded by criteria defined a priori.

### Table 2 Classification of asthma control according to guidelines

<table>
<thead>
<tr>
<th>Components of control</th>
<th>Controlled (all of the following)</th>
<th>Partly controlled</th>
<th>Uncontrolled</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptoms</td>
<td>≥2 days per week</td>
<td>&gt;2 days per week</td>
<td>Three or more features of partly controlled asthma present in any week</td>
</tr>
<tr>
<td>Night time awakenings</td>
<td>None</td>
<td>Any</td>
<td></td>
</tr>
<tr>
<td>Interference with normal activity</td>
<td>None</td>
<td>Any</td>
<td></td>
</tr>
<tr>
<td>SABA use for symptoms control</td>
<td>≥2 days per week</td>
<td>&gt;2 days per week</td>
<td></td>
</tr>
<tr>
<td>FEV₁ or PEF</td>
<td>Normal (&gt;80% of predicted/personal best)</td>
<td>&lt;80% of predicted/personal best</td>
<td></td>
</tr>
<tr>
<td>Validated questionnaires</td>
<td>Score</td>
<td>1–2</td>
<td>3–4</td>
</tr>
<tr>
<td>ATAQ⁰</td>
<td>0</td>
<td>0.75–1.5</td>
<td>≥1.5</td>
</tr>
<tr>
<td>ACQ¹</td>
<td>≥0.75</td>
<td>16–19</td>
<td></td>
</tr>
<tr>
<td>ACT²</td>
<td>≥20</td>
<td></td>
<td>≤15</td>
</tr>
</tbody>
</table>

**Notes:** ³Higher score indicates worsening of asthma control; ⁰lower score indicates worsening of asthma control.

**Abbreviations:** ACQ, Asthma Control Questionnaire; ACT, Asthma Control Test; ATAQ, Asthma Therapy Assessment Questionnaire; FEV₁, forced expiratory volume in 1 second; PEF, peak expiratory flow; SABA, short-acting β₂-agonists.
control, as shown in Table 3. At each step, a preferred option and alternatives are identified: when asthma is uncontrolled, treatment is required to be increased to the next step; by contrast, when asthma is controlled, a reduction in the amount of treatment may be organized. This process requires that asthma control is monitored by health care professionals and, preferably, by the patient at regular intervals. The frequency of follow-up assessments depends upon the patient’s initial clinical severity and the patient’s confidence in playing a role in his/her ongoing asthma control (self-management). Typically, patients are seen 1–3 months after the initial visit and every 3 months thereafter, but the interval is shorter after an exacerbation. A document specifically created to manage older asthmatics confirms these recommendations.

### Inhaled corticosteroids

Inhaled corticosteroids (ICS) are the cornerstone of asthma anti-inflammatory therapy. Guidelines recommend regular daily long-term ICS use for all subjects with uncontrolled or partly controlled asthma. In these conditions, several studies have demonstrated the efficacy of ICS in assuring asthma control. The decision of proper ICS dosing is based on the clinician’s judgment of the response to treatment. However, most benefits are achieved in adults at relatively low doses, equivalent to 0.2–0.4 mg of beclomethasone dipropionate (BDP) or equivalent per day that seldom sustain systemic effects even for long-term regular use. Increasing to higher doses provides relatively little further benefit in terms of asthma control, but increases the risk of side effects. The estimated comparative daily doses of different ICS through inhalers are reported in Table 4. Different ICS may marginally influence safety and effectiveness by several factors, such as oral bioavailability, different pharmacokinetics, and on-site activation into the lung. ICS are usually delivered via inhalers, either metered dose inhalers (MDI) or dry powder inhalers (DPI); although ICS can also be nebulized, this method of delivery is seldom used as current formulations are available as suspensions that have poor and variable lung drug delivery. Recently, the replacement of MDI propellants with more ecological formulations has permitted the modification of the characteristics of some ICS, delivering extra fine particles and increasing lung drug delivery; perhaps targeting smaller airways, some studies of real-life use attribute some advantages to these extra fine ICS with respect to traditional MDI, even at equipotent doses. ICS do not cure asthma and when they are discontinued, deterioration of control follows within weeks to months in most patients. However, not all asthmatics respond to ICS; failure of ICS treatment occurs in up to 25%–35% of patients. Asthmatic phenotypes characterized by neutrophilic inflammation of the airways are less likely to respond to ICS than those with prevalent eosinophilic inflammation. In older asthmatics neutrophilic airway inflammation is more common than in previous ages. Likewise, although extensive specific information is not available, clinical studies do not support that ICS in older adults have less efficacy than in younger ages. Probably, in real life nonadherence to ICS is a more important problem and particularly in older asthmatics.

| Table 3 Stepwise approach to asthma therapy |
|---|---|---|---|---|---|---|
| Step 1 | Step 2 | Step 3 | Step 4 | Step 5 | Step 6 |
| Preferred: | Preferred: | Preferred: | Preferred: | Preferred: | Step up when needed |
| SABA as needed | For 6–8 weeks | Low-dose ICS + LABA | Medium-dose ICS + LABA | High-dose ICS + LABA | (first check adherence, inhaler technique, and environmental control) |
| Low-dose ICS | Preferred: | Alternative: | Consider omalizumab and ICS for patients with allergies | Consider ICS and omalizumab for patients with allergies | Assess control: |
| LABA | Low-dose ICS | Medium-dose ICS + LABA | For at least 3 months |
| LTRA | Preferred: | Consider ICS and omalizumab for patients with allergies | |
| Alternative: | | Consider ICS and omalizumab for patients with allergies | |
| | | For at least 3 months | |

**Abbreviations:** ICS, inhaled corticosteroids; LABA, long-acting β₂-agonists; LTRA, leukotriene receptor agonist; SABA, short-acting β₂-agonists.

### Table 4 Estimated comparative daily dose of different ICS in milligrams for adults based upon the available efficiency data in the literature

<table>
<thead>
<tr>
<th>Name</th>
<th>Low</th>
<th>Medium</th>
<th>High dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>BDP–CFC MDI</td>
<td>&lt;0.4</td>
<td>0.4–0.8</td>
<td>&gt;0.8</td>
</tr>
<tr>
<td>BDP–HFA MDI</td>
<td>&lt;0.25</td>
<td>0.25–0.5</td>
<td>&gt;0.5</td>
</tr>
<tr>
<td>Budesonide DPI</td>
<td>&lt;0.4</td>
<td>0.4–0.8</td>
<td>&gt;0.8</td>
</tr>
<tr>
<td>Ciclesonide–HFA MDI</td>
<td>&lt;0.2</td>
<td>0.2–0.4</td>
<td>&gt;0.4</td>
</tr>
<tr>
<td>Fluticasone–HFA MDI or DPI</td>
<td>&lt;0.25</td>
<td>0.25–0.5</td>
<td>&gt;0.5</td>
</tr>
<tr>
<td>Triamcinolone–CFC MDI</td>
<td>&lt;0.75</td>
<td>0.75–1.5</td>
<td>&gt;1.5</td>
</tr>
<tr>
<td>Flunisolide–CFC MDI</td>
<td>&lt;1</td>
<td>1–2</td>
<td>&gt;2</td>
</tr>
<tr>
<td>Flunisolide–HFA MDI</td>
<td>&lt;0.32</td>
<td>0.32–0.64</td>
<td>&gt;0.64</td>
</tr>
<tr>
<td>Mometasone DPI</td>
<td>&lt;0.4</td>
<td>0.4–0.8</td>
<td>&gt;0.8</td>
</tr>
</tbody>
</table>

**Abbreviations:** ICS, inhaled corticosteroids; CFC, chlorofluorocarbon; DPI, dry powder inhaler; HFA, hydrofluoroalkane; MDI, metered dose inhaler; BDP, beclomethasone dipropionate.
of ICS than previous ages. Most older patients admitted to emergency departments for asthma symptoms were not using ICS. In another group of 6254 elderly adults consecutively admitted to hospital with asthma in Ontario, those patients identified as users of ICS post-discharge were respectively 29% readmitted referrals to hospital and 30% of those who died over a 1-year follow-up period.

**Inhaled beta-agonists**

Inhaled β₂-agonists are the most effective reliever in asthma. According to the duration of action, they are classified into either short-acting β₂-agonists (SABAs) or long-acting β₂-agonists (LABAs). Albuterol is by far the most commonly used SABA. Formoterol and salmeterol are the most commonly used LABAs. Formoterol, like albuterol, is a fast-acting reliever. Albuterol and (in some countries) formoterol are not only available by inhalation, but also by nebulization. There is no clinical difference between different devices for β₂-agonists' delivery. However, inhalers are less cumbersome and more convenient than nebulizers and preferred if proper inhaler technique is obtained.

The number of β₂-adrenergic receptors on the smooth airway muscles decrease with aging. The response to SABAs has been shown to decline with age and older asthmatics admitting to emergency rooms may be less responsive to albuterol than younger asthmatics. By contrast, current studies do not support that LABA use in older adults is less effective than in younger ages.

Guidelines recommend that asthmatics should have access to an inhaled fast-acting bronchodilator for rescue from acute symptoms. SABAs should not be utilized more than 2–3 times a week because regular use of SABAs alone is dangerous. LABAs should never be used alone as long-term regular monotherapy for asthma because they may be dangerous. When a low to medium ICS dose alone is unable to control asthma, the addition of an LABA has advantageous effects on lung function, symptoms, and exacerbations. LABAs and ICS can be administered either separately or combined. Manufacturers have produced a combination of LABAs and ICS in a single inhaler, suggesting that it can optimize adherence with respect to separate inhaler use. Effectively, they ensure that LABAs are necessarily accompanied by ICS and their use is now widespread in real life. Even if used concomitantly with ICS, adverse effects of LABAs are not necessarily a nonissue and they should be stopped when possible. Concerns remain about the ultimate major cardiovascular safety of LABAs. Nevertheless, minor adverse outcomes are common in older asthmatics using LABA/ICS combinations at daily recommended dosages: a survey found that, 41% and 51% of patients reported side effects attributed to ICS and LABA, respectively; the most common side effects were voice changes, sore throat, and tremors.

LABAs/ICS are currently used as a twice – daily regimen, but efforts have been made to develop a once-daily combination to simplify treatment and, possibly, increase adherence: indacaterol/mometasone, and vilanterol/fluticasone furoate are being developed and are two possible options.

**Leukotriene receptor antagonists**

Several studies have demonstrated that leukotriene receptor antagonists (LTRAs) are well tolerated and improve asthma control at all ages, including the elderly. LTRAs seem to be particularly useful in asthmatics with concomitant rhinitis, and who smoke. Once-daily orally administered montelukast is the most prescribed LTRA. When used alone, LTRAs are not as effective as ICS, but they are the first alternative to ICS in older asthmatics who prefer a nonsteroid drug or who cannot tolerate ICS. LTRAs are used as an alternative to LABAs in addition to ICS, but the combination treatment of LABAs/ICS has more efficacy. Recently, LTRAs have been proposed in the elderly with difficult-to-treat asthma for steroid resistance.

**Biological agents**

Several biological agents are in advanced phases of study in asthma, but only omalizumab, a monoclonal antibody directed against serum immunoglobulin E (IgE), is currently a therapeutic option in severe asthmatics, including the elderly. Omalizumab is used as add-on therapy in allergic patients with elevated serum levels of IgE and severe asthma uncontrolled with high doses of ICS, or requiring systemic corticosteroids, where it reduces the incidence of exacerbations, emergency room visits, and improves quality of life. Omalizumab is administered as a subcutaneous injection every 2 to 4 weeks depending on dose. Its cost is higher than that of other asthma therapies. There is no evidence of a persistent beneficial effect after stopping its use. It has marked variability in response, being, to date, not clear what differentiates a responder from a nonresponder. The most common side effects of omalizumab are local symptoms at the site of injection, and with a small risk of anaphylaxis, corresponding to 0.09% of cases in post-marketing surveillance studies.

**Systemic corticosteroids**

A goal of asthma management is to achieve disease control with no or minimal use of systemic corticosteroids. In fact,
although systemic corticosteroids are very effective in asthma, their prolonged use is limited by the risk of significant adverse effects, such as adrenal failure, osteoporosis, diabetes mellitus, cataract, glaucoma, hypertension, psychosis, skin bruising, muscle weakness, gastritis, and peptic ulcer that warrant caution and monitoring.\(^1\)\(^-\)\(^4\) However, long-term systemic corticosteroid use is sometimes required for severely uncontrolled asthma or as a burst to treat exacerbations. To this aim, oral prednisolone at daily dose of 0.5–1.0 mg/kg or equivalent is often given for at least 5 days,\(^5\)\(^-\)\(^6\) but the doses and duration should be individualized based on previous or current response. In addition, corticosteroids are also used for controlling a variety of diseases and in the elderly their weaning is a bigger challenge than in younger ages. Tapering is necessary after long-term use or recurrent bursts with systemic corticosteroids. Out of emergency oral preparations are preferred to intravenous and intramuscular formulations because they are equally effective and more practical.

**Inhaled anticholinergics**

Inhaled ipratropium, the most commonly used short-acting anticholinergic, is not a first-choice as a reliever, being less effective than \(\beta_2\)-agonists. However, some elderly patients have a particularly good response to anticholinergics.\(^6\)\(^1\) In uncontrolled asthma, despite ICS/LABA use, the addition of once-daily tiotropium may give a significant improvement in forced expiratory volume in 1 second (FEV\(_1\)) and symptoms.\(^6\)\(^2\) In many countries, tiotropium is available with either the DPI HandiHaler\(^®\) (Pfizer, Inc, New York, NY, USA) or the soft mist inhaler Respimat\(^®\) (Boehringer Ingelheim, Ingelheim, Germany). However, the release of tiotropium via Respimat has been associated with an increase in deaths, mainly in the elderly with known cardiac rhythm disorders, so it is advisable to use the DPI for its delivery until the current concerns are excluded.\(^6\)\(^3\) Possibly, tiotropium and other long-term anticholinergics might be useful as add-on treatment in moderate to severe asthma, but currently their use is off-label and has not yet translated into specific treatment guidelines.\(^6\)\(^2\)

**Other treatments**

Theophyllines, usually used as oral sustained-release formulations, are a third-choice, but may provide a benefit as add-on therapy in patients who do not achieve control with ICS/LABAs.\(^1\)\(^-\)\(^3\) They have a relatively small therapeutic index with significant side effects, particularly at higher doses and in the elderly.\(^2\)\(^5\)

Long-term use of macrolides is gaining popularity in neutrophilic forms of difficult-to-treat asthma.\(^6\)\(^4\)\(^-\)\(^6\) It is not clear if the beneficial effect of macrolides is due to antibiotic or immunomodulatory effects.

Roflumilast, a phosphodiesterase-4 inhibitor with anti-inflammatory properties, has shown some efficacy with tolerable gastrointestinal side effects in patients with mild to moderate asthma.\(^6\)\(^7\) Further trials are necessary to determine its role in asthma treatment.

Immunosuppressers, such as methotrexate, cyclosporins, tacrolimus, azathioprine, and gold salts are seldom used in asthma because they sustain a variety of side effects that usually do not offset their steroid-sparing effect.\(^3\)

Bronchial thermoplasty is a relatively safe bronchoscopic procedure in which radiofrequency energy is used to reduce bronchial smooth muscle wall thickness. If more clinical data will confirm its potential, bronchial thermoplasty might eventually become an option in severe asthma resistant to pharmacological management.\(^6\)\(^8\)

**Trigger avoidance and the role of comorbidities**

Allergy has a well-known role in asthma, even if, overall, it seems to wane with age.\(^6\)\(^9\)\(^-\)\(^7\)\(^0\) However, asthma in the elderly may be associated with allergic triggers.\(^7\)\(^0\) There is scarce evidence about whether measures to create a low-allergen environment are effective for improving asthma control in the elderly. The role of specific immunotherapy in elderly asthmatics is limited, but specific allergen immunotherapy may be an appropriate adjunctive therapy when a clear relationship exists between symptoms, allergen exposure, and positivity to a skin test.\(^7\)\(^1\)

Asthma exacerbations are often sustained in the elderly by a variety of nonallergenic triggers, such as viral infections, pollutants, and drugs. Elderly asthmatics often perceive viral infections as common triggers and two thirds reported seasonal worsening in winter.\(^7\)\(^2\) Patients with moderate to severe asthma should be advised to receive an influenza vaccination every year; they are safe and have a small risk of pulmonary complications.\(^7\)\(^3\) From the 1991–2002 Medicare Survey, 72% of older subjects received influenza vaccinations.\(^7\)\(^4\)

Several epidemiologic studies suggest an association between outbreaks of asthma exacerbations and exposures to air pollutants;\(^7\)\(^5\) environmental tobacco smoke is an important and modifiable air pollutant.\(^7\)\(^3\) Surprisingly, active smoking is common among asthmatics.\(^7\)\(^5\) Asthmatics who smoke often have poor disease control\(^7\)\(^6\) and diminished responsiveness to ICS\(^7\)\(^4\)\(^-\)\(^7\)\(^7\) and systemic corticosteroids.\(^7\)\(^8\) It is generally believed that the damage from smoking has already been done in the elderly, but, although more beneficial when achieved early,
Role of education

The role of education in asthma management is essential and its key components are displayed in Table 6.1–4

The main goals of education are to achieve the patient’s self-management and improve adherence. Self-management requires not only the acquisition of knowledge and skills, but also behavior changes in order to achieve positive health effects.89 Even if older asthmatics may be more prone to accept a passive approach and be less involved or not seek out information,90 self-management is possible and effective even in the elderly and may also contribute to improve adherence.93–95

Adherence is defined as the degree to which patient behaviors coincide with the recommendations of health care providers.96 Adherence is a major problem for treatment of all chronic diseases, including asthma. Nonadherence significantly contributes to asthma mortality,97 hospitalizations,98 high health care costs,99 and increased exacerbations.90 It is useful to distinguish between intentional and unintentional nonadherence. Intentional nonadherence occurs when the patient decides either not to take the drug, to only take it from time to time, or to take a different dosage than prescribed.96 Possibly, at similar baseline conditions, older asthmatics have the same degree of intentional nonadherence with respect to previous ages, even if in real life they often suffer from conditions predisposing them to nonadherence, such as polypharmacy and depression.100,101 Unintentional nonadherence occurs when a patient involuntarily does not follow medical prescriptions.90 Poor inhaler technique is a variety of unintentional nonadherence98 and it is common in asthma, as the most important drugs used for its manage-

Table 6 Key components of a personalized asthma education program

| Develop good patient–doctor partnership |
| Discuss the nature of the disease and its pathophysiology |
| Evaluate patient’s triggers |
| Identify patient’s goals and preferences |
| Develop a self-monitoring plan in how to monitor symptoms and lung function |
| Discuss patient’s lifestyle and change options that are useful for better asthma control according to patient’s goals and preferences |
| Evaluate treatment regimens according to patient’s goals and preferences |
| Discuss comorbidities and their treatment including over-the-counter medications, drops, and health food preparations |
| Share and document decisions about treatment, lifestyle regimens, and trigger avoidance according to the patient’s goals |
| Share a written asthma action plan for the early recognition and treatment of exacerbations, including when and how early to access health care providers for unscheduled visits or emergencies |
| Teach proper inhaler technique with practical examples using the prescribed placebo inhaler |
| Schedule follow-up appointments according to patient’s availability |
| Control and document asthma control at each follow-up visit |
| Control and document comorbidities, their treatment, and possible drug–drug interactions at each follow-up visit |
| Control and document effectiveness of the trigger avoidance program at each follow-up visit |
| Control and document effectiveness of lifestyles program at each follow-up visit |
| Control and document adherence to shared treatment at each follow-up visit |
| Control and document inhaler technique at each follow-up visit |

Table 5 Main asthma-related comorbidities

| Rhinitis/rhinosinusitis |
| Gastro-esophageal reflux disease |
| Obesity |
| Obstructive sleep apnea syndrome and other sleep-disordered breathing |
| Chronic obstructive pulmonary disease |
| Psychopathologies, mainly depression |
| Tobacco smoking |
| Osteoporosis |
| Dysfunctional breathing/vocal cord dysfunction |
| Hormonal disorders |
| Hypertension, diabetes, ischemic heart disease, degenerative joint disease/arthritis, cardiac arrhythmia, congestive heart failure, cerebrovascular disease/atherosclerosis* |

Note: *Probably increased.
ment are administered by inhalation. The effective use of inhalers is critically dependent upon the patient’s ability to utilize the device properly. Although inhaler misuse may be due to a poor device choice for an individual patient, more often it occurs for lack of proper education. Unfortunately, poor inhaler technique is commonly observed for all inhaler devices, is associated with poor asthma control, and with increased age. The most important modifiable factors associated with improved inhaler use for both MDI and DPI are the provision of instructions (practical education being better than verbal) at the first prescription and regular checks at each follow-up visit by trained health caregivers. Because the problem of inhaler misuse is neglected by patients and physicians, inhaler education should be an integral part of the routine management of any asthmatic patient.

Conclusion
Current guidelines do not include specific sections for the management of asthma in the elderly, supporting the view that drugs that are useful in managing asthma in the elderly are as effective as for other age groups. This is only partially evidence-based, as many randomized trials of treatment exclude older asthmatics. According to this view, other reasons explain the greater percentage of uncontrolled asthma in the elderly, with increased morbidity and mortality.

A first cause is that many elderly patients perceive or tolerate substantial asthma symptoms, perhaps having low expectations about the degree of control that is possible. A second cause is that older asthmatics often suffer from many other comorbidities, which, directly or by treatment, may worsen the control of asthma. Possibly, patients and physicians often make tradeoffs with these comorbidities and do not treat asthma, considering it to be less dangerous. Importantly, guidelines do not include specific extensive sections for patients with multiple comorbidities and polypharmacy, a very common situation in the elderly; when guidelines describe possible interactions between diseases and with other drugs taken concomitantly, the discussion is superficial and limited to a few generic warnings, while drug–drug interactions often largely contribute to worsen asthma control in older adults. This calls for a shift in clinical research towards more pragmatic trials to generate more applicable evidence according to the peculiarities and the needs of older asthmatics. A third cause is poor adherence. It also includes inhaler misuse, which is particularly common in the elderly and often not contrasted efficiently.

We conclude that despite the fact that a variety of treatment options for good asthma management are available, in real life many elderly asthmatics suffer from poor disease control. The main reasons are that older asthmatics tolerate or do not perceive poor symptom control, are not encouraged to develop self-management, and have poor adherence to medications including common inhaler misuse. Concomitant comorbidities and/or related treatments may also contribute to poor asthma control. Identification and use of specific instruments addressed to evaluate asthma control in the elderly with concomitant comorbidities as well as measurements for improving self-management and adherence are needed for better asthma control in the elderly.

Disclosure
AS Melani has served as an advisory board member, has been reimbursed for speaker honoraria, and has received fees as a consultant for Chiesi, Menarini, Novartis, Mundipharma, GSK, Sanofi-Aventis, and Artsana. There was no source of financial support for the present manuscript. The author reports no other conflicts of interest in this work.

References


51. Chauhan BF, Ducharme FM. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev. 2012;5:CD003214.


